Open this publication in new window or tab >>Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Paediatric Inflammation, Metabolism and Child Health Research.
Paracelsus Med Univ, Dept Pediat, Salzburg, Austria.;Paracelsus Med Univ, Obes Res Unit, Salzburg, Austria..
Paracelsus Med Univ, Dept Pediat, Salzburg, Austria.;Paracelsus Med Univ, Obes Res Unit, Salzburg, Austria..
Paracelsus Med Univ, Dept Pediat, Salzburg, Austria.;Paracelsus Med Univ, Obes Res Unit, Salzburg, Austria..
Paracelsus Med Univ, Obes Res Unit, Salzburg, Austria.;Salzkammergutklinikum Voecklabruck, Dept Pediat & Adolescent Med, Voecklabruck, Austria..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Paediatric Inflammation, Metabolism and Child Health Research.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cardiology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Uppsala Clinical Research Center (UCR).
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Paediatric Inflammation, Metabolism and Child Health Research.
Paracelsus Med Univ, Dept Pediat, Salzburg, Austria.;Paracelsus Med Univ, Obes Res Unit, Salzburg, Austria..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Paediatric Inflammation, Metabolism and Child Health Research.
Show others...
2025 (English)In: Cardiovascular Diabetology, E-ISSN 1475-2840, Vol. 24, no 1, article id 324Article in journal (Refereed) Published
Abstract [en]
Background
Patients with obesity during childhood have an increased risk of fatal and non-fatal cardiovascular events during adulthood. The severity of obesity is commonly determined by BMI. However, children with relatively low BMI may have high cardiometabolic risk. Indeed, BMI-based obesity classifications might miss children at high cardiometabolic risk. Insulin has been suggested as a marker of cardiometabolic risk. In this study, we therefore estimated and compared cardiometabolic risk using either the BMI standard deviation score (BMI-SDS) or fasting insulin in an international cohort of children and adolescents with obesity and lean controls.
Methods
Study participants (712 with obesity and 99 lean controls), aged 3 to 18 years, were categorized according to their BMI-SDS as lean or obesity class I, II, or III, or by their fasting insulin quartiles as quartile 1, 2, 3, or 4 with the lean subjects in a separate control group. Prevalence of cardiometabolic risk factors was assessed in each group. Sensitivity and specificity analyses for cardiometabolic risk were conducted for both BMI-SDS and fasting insulin. Multiple regression, logistic regression, and receiver operating characteristic (ROC) analyses were performed between fasting insulin, BMI-SDS and cardiometabolic risk factors.
Results
An elevated prevalence of the cardiometabolic risk factors dyslipidemia, dysglycemia and hypertension was observed in both increasing BMI-SDS classes and increasing fasting insulin quartiles. Fasting insulin demonstrated higher areas under the curve (AUC) for detecting dyslipidemia, dysglycemia, and the combination of dyslipidemia, dysglycemia, and hypertension, compared to BMI-SDS. BMI-SDS demonstrated a higher AUC for detecting hypertension compared to fasting insulin. The same patterns were seen for the logistic regression. However, fasting insulin had an overall stronger association with the cardiometabolic risk factors studied compared to BMI-SDS.
Conclusions
In children and adolescents with obesity, fasting insulin provides complementary information to BMI-SDS in identifying those with elevated cardiometabolic risk factors. While neither marker alone offers strong predictive accuracy, incorporating fasting insulin into clinical assessment may help prioritize individuals who require more detailed evaluation. An elevated fasting insulin value may warrant further investigation among children and adolescents with obesity, independent of obesity class based on BMI-SDS.
Place, publisher, year, edition, pages
BioMed Central (BMC), 2025
Keywords
Obesity, Pediatric obesity, Hypertension, Cardiometabolic risk, Cardiovascular disease, Dysglycemia, Dyslipidemia, Insulin, Cardiovascular risk factors, BMI-SDS
National Category
Endocrinology and Diabetes Cardiology and Cardiovascular Disease Pediatrics
Identifiers
urn:nbn:se:uu:diva-566343 (URN)10.1186/s12933-025-02882-7 (DOI)001547708400001 ()40781672 (PubMedID)2-s2.0-105012765077 (Scopus ID)
Funder
EU, FP7, Seventh Framework Programme, 279153Swedish Foundation for Strategic Research, CMP22-0014Swedish Research Council, 2016-01040
Note
Correction in: Cardiovascular Diabetology, vol. 24, article id 417, DOI: 10.1186/s12933-025-02975-3
Title in the list of papers of Rasmus Stenlid's thesis: Fasting insulin better predicts cardiometabolic risk factors in children and adolescents with obesity than BMI
2025-09-082025-09-082026-04-22Bibliographically approved